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1. Introduction 
Cancer is a leading cause of death worldwide; nearly 1 in 6 
deaths is reported due to cancer.1 There was 14.1 million new 
cancer cases and 8.2 million cancer deaths in 2012. This global 
burden is expected to increase to 21.7 million new cases and 13 
million cancer deaths by 2030.2 Thus, there is an urgent need to 
develop new drugs and/or use new strategies to combat cancer. 
Over the last decades, several chemical compounds either 
naturally or synthetically grabbed scientists' attentions for their 
anticancer activity; however, the situation is far from satisfactory, 
due to the toxicity related to nonspecific accumulation or their 
hydrophobicity, which are considered critical challenges for 
clinical applications. Therefore, developing a strategy to improve 
the physicochemical property of existing drugs will be required. 
Curcumin (diferuloylmethane) is a hydrophobic polyphenol 
compound derived from Curcuma Longa (turmeric), has attracted 
attention as a promising natural product.3 An extensive research 
indicated that curcumin possesses several chemopreventive and 
pharmacological activities,4,5 including potent antioxidant6 and 
antitumor properties7 with extremely superior safety profiles.8-10 
Its anticancer activities are mediated through the inhibition of 
NF-ĸB activity occurring through the down-regulation of IKK.11 
Another study conducted by Gopinath et al. has provided 
evidence that curcumin decreases protein damage by quenching 
free radicals.12 Moreover, it can improve the cytotoxicity of some 
other anticancer molecules against different cancer cells.13 In 
spite of the promising biological effects of curcumin at the 
preclinical level, it fails clinically because of its poor 
bioavailability,14,15 rapid metabolism, and excretion.16,17 Thus, it 
will be beneficial to improve the physiochemical property of 
curcumin for the therapeutic applications.  
Doxorubicin (Dox), which belongs to anthracycline antibiotic 
family, extracted from the bacteria Streptomyces pecetius,18 is 
one of the most vital antitumor compounds. Dox is highly 
effective in the treatment of various types of cancer including 
breast, acute lymphocytic leukemia, bladder, and prostate 
cancer.19-22 It has a unique mechanism of action through 
inhibition topoisomerase II, which interfere with DNA through 
insertion, inducing cancer cell apoptosis.23 Similar to curcumin, 
Dox has limited clinical use, due to its pharmacokinetic 
properties, such as short half-life and a high cumulative dose, 
leading to dose-independent side effects.24 
Furthermore, the conventional single treatment can lead to the 
development of drug resistance over the course of therapy.25 
Recently, combinational chemotherapy has emerged as one of the 
strategies that have gained attention to surmount the associated 
problems with the effectiveness of cancer treatment by reducing 
side effects and overcoming drug resistance, thereby achieving 
synergistic therapeutic efficacy.26,27 Additionally, the treatment 
success hinges on appropriate control over the timing, extent, and 
location of dosing. In this regard, drug delivery system 
techniques play an important role towards increasing the efficacy 
of the drug by delivering it to where it is needed, at the correct 
dose and extended release over a desired period.28-30  
Our group has reported the use of the cyclic amphiphilic 
peptide as a drug delivery system.31-33 Moreover, the amphiphilic 
peptide was expected to increase the solubility of hydrophobic 
molecules such as curcumin.34 Dox is a hydrophilic anticancer 
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agent. Cyclic [W(RW)4]-Dox significantly inhibited the 
proliferation of human leukemia (CCRF-CEM) and breast 
carcinoma (MDA-MD-468) cells and showed 3.6–fold higher 
cellular uptake than Dox alone in SKOV-3 cells.33 We
 
Scheme 1. Synthesis of cyclic amphiphilic peptide [C(WR)4K2(β-A)] (4). 
hypothesized that physicochemical and/or biological properties 
of curcumin could be improved by using an amphiphilic cyclic 
peptide-Dox conjugate. Here we report the synthesis and 
evaluation of an anticancer agent using a cyclic amphipathic 
peptide.  
2. Results and discussion 
2.1. Chemistry 
We have previously reported that cyclic peptides containing 
alternative tryptophan and arginine residues act as a molecular 
transporter.31,34 Here, a trifunctional cyclic peptide was prepared 
through conjugation of two anticancer drugs with a cell-
penetrating cyclic peptide in multiple steps to improve the 
physicochemical properties and biological activities. 
First, amphiphilic cyclic peptide [C(WR)4K2(β-A)] was 
synthesized using Fmoc/tBu solid phase peptide chemistry.31 
Fmoc and side chain-protected amino acids, mainly tryptophan, 
arginine, cysteine, lysine, and β-alanine were assembled on 
preloaded Trp(Boc)-2-chlorotrityl resin (1) to generate side 
chain-protected linear peptide (2). Piperidine (20% v/v) in DMF 
was used to remove Fmoc group at N-terminal, followed by the 
cleavage of the protected peptide from the resin with agitation in 
a mild acidic solution  (dichloromethane (DCM), trifluoroethanol 
(TFE), and acetic acid) to generate the linear peptide with a free 
carboxylic group (3).35 Under diluted and anhydrous conditions, 
the linear protected peptide (3) was cyclized using coupling 
reagents, N,N’-diisopropylcarbodiimide (DIC) and 1-hydroxyl-7-
azabenzotriazole (HOAt), followed by side chain deprotection 
generating the targeted amphiphilic cyclic peptide [C(WR)4K2(β-
A)] (4) (Scheme 1). The chemical structure of the conjugate 
confirmed by MALDI-TOF/TOF MS, showing the peak 1883 
Da, corresponding to [M + H]+.  
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Scheme 2. Synthesis of Dox-SS-Pyridyl (6) and Dox-cyclic peptide conjugate (7). 
Cyclic peptide [C(WR)4K2(β-A)] was used for conjugation 
with Dox through cysteine and using a disulfide bond. The 
disulfide linkage is relatively stable in extracellular 
compartments as compared to intracellular tumor fluid, where it 
gets hydrolyzed due to elevated glutathione (GSH) 
concentration.36-39 Therefore, Dox was modified with sulfhydryl 
group and activated using dithiodipyridine to generate Dox-SS-
Pyridyl compound (6) (Scheme 2). The modified Dox (6) was 
conjugated with the thiol group on a cysteine residue of the 
cyclic peptide (4) under aqueous conditions affording Dox-SS-
cyclic peptide (7) (Scheme 2). MALDI spectra showed a distinct 
peak at 2529 Da corresponding to [M + 4]+, in addition to two 
fragments one related to extrusion tetracyclic anthracycline 
aglycone at 2131 Da and other for protonated cysteinyl peptide at 
1887 Da, which may be due to specific fragmentation of disulfide 
bond under MALDI-MS.40 
 
Curcumin (8) was modified with glutaric anhydride41 using a 
ring opening reaction of through a nucleophilic attack of one of 
the phenolic group under on anhydride carbonyl group under a 
basic condition, forming a stable ester linkage containing a free 
carboxylic group as shown in Scheme 3. The synthesis of 
monofunctional curcumin (9) permits the presence of one free 
phenolic group which is found important for the antioxidant 
activity of the molecule. The presence of glutarate chain 
decreases the steric hindrance for conjugation with the cyclic 
peptide- attached Dox (7).  
 
Dox-peptide-curcumin conjugate (DPCC) 10 was synthesized 
by amide coupling reaction between the amine group of the 
doxorubicin-cyclic peptide (7) and the monocarboxylic acid 
group of curcumin compound (9) using phosphonium 
hexafluorophosphate (PyBOP) and 1-hydroxybenzotriazole 
derivatives (HOBt) under basic medium at room temperature for 
three hours.42 The targeted compound was analyzed by MALDI, 
showing the peak at 2993 Da corresponding to [M + 4]+. In 
addition to two fragments 2597 and 2351 Da related to extrusion 
tetracyclic anthracycline aglycone and protonated cysteinyl 
peptide as described above previously. (Scheme 3). 
 
2.2. The cytotoxicity assay of the synthetic compounds 
The cytotoxicity of all compounds was tested in two different 
cancer cell lines, human leukemia carcinoma cells (CCRF-CEM), 
human ovarian carcinoma cells (SKOV-3), in addition to normal 
kidney cell line (LLCPK), using MTS assay with concentration 5 
µM and incubation time 24 h (Figure 1)and 72 h (Figure 2). 
Curcumin did not inhibit the proliferation of CCRF-CEM cells 
as expected because of low solubility and precipitation in cell 
culture media. Cyclic peptide (4), Dox-attached cyclic peptide 
(7), and DPCC (10) showed less cytotoxicity than Dox after 24 h 
incubation. Dox-attached cyclic peptide (7) reduced the cell 
proliferation by 73% after 72 h, but it was still less cytotoxic than 
Dox alone (79%). The non-covalent physical mixture between 
Dox, the cyclic peptide, and curcumin reduced the cell 
proliferation by 78% and 84%, slightly higher than that of Dox 
(77% and 79%) after incubation 24 h and 72 h, respectively. 
Moreover, the physical mixture of Dox and the cyclic peptide 
exhibited slightly more inhibition when compared with Dox 
alone, showing 78% versus 77% after 24 h, and 82% versus 79% 
after 72 h incubation.  
In ovarian carcinoma cell line (SKOV-3), Dox-attached cyclic 
peptide (7) was found to be more cytotoxic as compared to 
compound DPCC (10)  and reduced the cell proliferation by 55% 
versus 30%, but still less active than Dox (62%) after 72 h 
incubation. The physical mixing of Dox, [C(WR)4K2(β-A)], and 
curcumin reduced the cell proliferation by 34% and 80%, a 
slightly higher than Dox (22% and 62%) after 24 h and 72 h 
incubation, respectively. Similarly, the physical mixture of Dox 
and the peptide showed slightly higher inhibition when compared 
with Dox (32% versus 22%) after 24 h incubation (Figures 1 and 
2).  
 
Scheme 3. Synthesis of curcumin monoglutarate (9) and Dox-Cyclic Peptide-curcumin Conjugate (10). 
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In normal kidney cell line, cyclic peptide (4) was not 
cytotoxic, but Dox-SS-cyclic peptide (7) and Dox-cyclic peptide-
curcumin (10) exhibited less than 37% and 31% cytotoxicity, 
respectively, after 24 h. On the other hand, the physical mixture 
of the cyclic peptide, curcumin, and Dox showed cytotoxicity 
(50%) comparable to Dox (50%) after 24 h incubation but was 
less toxic than Dox  (55% vs 60%) after 72 h incubation. 
Regarding the physical mixture between the cyclic peptide and 
Dox, it showed slightly higher toxicity than Dox (51% versus 
50%) after 24 h incubation but was slightly less toxic than Dox 
(58% versus 60%) after 72 h incubation (Figures 1 and 2). 
 
  
Figure 1. Comparison of cytotoxicity between Dox (5 µM), curcumin (5 
µM), and cyclic peptide (5 µM), Dox-SS-cyclic peptide (5 µM), DPCC (5 
µM), and the corresponding physical mixture Dox (5 µM), cyclic peptide (5 
µM), and curcumin (5 µM) against human leukemia, ovarian carcinoma cells 
and normal kidney cell after 24 h. 
 
 
Figure 2. Comparison of cytotoxicity between Dox (5 µM), curcumin (5 
µM), and cyclic peptide (5 µM), Dox-SS-cyclic peptide (5 µM), DPCC (5 
µM), and the corresponding physical mixture Dox (5 µM), cyclic peptide (5 
µM), and curcumin (5 µM) against human leukemia, ovarian carcinoma cells 
and normal kidney cell after 72 h. 
 
One of the major problems found with the anticancer agents 
is their cytotoxicity to both normal and cancer cells. As shown in 
Figure 2, Dox was cytotoxic (60-79%) in all three cell lines after 
72 h incubation. However, selective cytotoxicity was observed on 
leukemia and ovarian carcinoma cells by  DPCC (10) and cyclic 
peptide-doxorubicin conjugate 7 in comparison to normal kidney 
cell lines after 72 h incubation. Compounds 7 and 10 did show 
any inhibition for the proliferation of normal kidney LLCPK 
cells after 72 h incubation. On the other hand, compounds 7 and 
10 exhibited inhibition of proliferation of CCRF-CEM (73% and 
41%, respectively) and SKOV-3 (55% and  30%, respectively) 
cells under similar conditions, suggesting selectivity of these 
compounds towards cancer cells. The data demonstrate selective 
cytotoxic effect by DPCC (10) and cyclic peptide-Dox conjugate 
7 in cancer cells.  
 
Conclusions 
A synthetic methodology was developed for the synthesis of a 
conjugate containing an amphipathic cyclic peptide, Dox, and 
curcumin. The cyclic amphiphilic peptide containing lysine and 
cysteine residues was synthesized using Fmoc/tBu solid phase 
methodology. Both curcumin and Dox were modified by the 
reaction of glutaric anhydride and 2-iminothiolane, respectively. 
Dox-cyclic peptide (7) was reacted with curcumin monoglutarate 
to Dox-cyclic peptide-curcumin, which was characterized by 
MALDI-TOF. The purity of the compounds was confirmed by 
analytical HPLC. The antiproliferative assay of the synthesized 
compounds showed that Dox-cyclic peptide conjugate exhibited 
a significantly higher cytotoxicity than the corresponding DPCC 
(10) but still less than Dox in human leukemia and human 
ovarian carcinoma cells. The physical mixture of Dox, 
[C(WR)4K2(β-A)] and curcumin showed a considerable activity 
higher than Dox after 24 h and 72 h incubation. Overall, DPCC 
(10) and compound (7) were found to be more selective towards 
cancer cells vs normal cells used after 72 h incubation.  
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Highlights 
 
 
• Doxorubicin and curcumin were conjugated 
with a cell-penetrating peptide. 
• Doxorubicin-peptide-curcumin conjugate 
(DPCC) was synthesized.  
• DPCC was found to be more cytotoxic 
against cancer cells versus normal cells. 
 
